Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 4/20 | 0.49 |
| ▸ | PLK1 | P53350 | 4/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.41 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.41 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2488807 | 0.88 | CYP2C19 (0.50) | CYP2C19PLK1KCNH2CYP3A4ALDH1A1 | |
| SCHEMBL10034408 | 0.84 | CYP2C19 (0.52) | CYP2C19PLK1KCNH2CYP3A4ALDH1A1 | |
| SCHEMBL28411478 | 0.82 | MAPT (0.37) | ALDH1A1TSHRTDP1HPGDTXNRD1 | |
| SCHEMBL18517038 | 0.81 | CYP2C19 (0.50) | CYP2C19PLK1KCNH2CYP3A4ALDH1A1 | |
| SCHEMBL2486931 | 0.81 | TOP2A (0.33) | CYP2C19HPGD | |
| SCHEMBL2489377 | 0.80 | TOP2A (0.33) | CYP2C19 | |
| SCHEMBL21226008 | 0.79 | CYP2C19 (0.50) | CYP2C19PLK1KCNH2CYP3A4ALDH1A1 | |
| SCHEMBL2890931 | 0.78 | KCNH2 (0.50) | CYP2C19PLK1KCNH2CYP3A4ALDH1A1 | |
| SCHEMBL28496780 | 0.78 | PLK1 (0.47) | CYP2C19PLK1KCNH2CYP3A4ALDH1A1 | |
| SCHEMBL2492296 | 0.75 | CYP2C19 (0.69) | CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011132070-A1 | PROCESS FOR THE PREPARATION OF 2-AMINO-SUBSTITUTED 1,3-BENZOTHIAZINE-4-ONES | MAKAROV VADIM A (RU) | 2011-10-27 | — | — | WO | claimed |
| EP-2380886-A1 | Process for the preparation of 2-aminosubstituted 1,3-benzothiazine-4-ones | Makarov Vadim A. (RU) | 2011-10-26 | — | — | EP | claimed |
| WO-2025032611-A1 | BENZO[de]ISOQUINOLINE-1,3-DIONE BASED COMPOUND AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2025-02-13 | — | — | WO | disclosed |
| CN-108440446-B | Benzothiazine-4-ketone compound containing oximino fragment and preparation method thereof | 中国医学科学院医药生物技术研究所 | 2020-05-15 | — | — | CN | disclosed |
| EP-2640712-B1 | 2-PIPERAZIN-1-YL-4H-1,3-BENZOTHIAZIN-4-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF MAMMALIAN INFECTIONS | ECOLE POLYTECHNIQUE FED LAUSANNE EPFL (CH) | 2018-07-11 | — | — | EP | disclosed |
| US-8796264-B2 | 2-piperazin-1-yl-4H-1,3-benzothiazin-4-one derivatives and their use for the treatment of mammalian infections | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2014-08-05 | — | — | US | disclosed |
| EP-2640712-A1 | 2-PIPERAZIN-1-YL-4H-1,3-BENZOTHIAZIN-4-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF MAMMALIAN INFECTIONS | Ecole Polytechnique Fédérale de Lausanne (EPFL) (CH) | 2013-09-25 | — | — | EP | disclosed |
| US-20130245007-A1 | 2-PIPERAZIN-1-YL-4H-1,3-BENZOTHIAZIN-4-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF MAMMALIAN INFECTIONS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2013-09-19 | — | — | US | disclosed |
| WO-2013038259-A1 | BENZOTHIAZINONE DERIVATIVES AS ANTI -TUBERCULOSIS AGENTS | THE UNIVERSITY OF QUEENSLAND (AU) | 2013-03-21 | — | — | WO | disclosed |
| EP-2570413-A1 | Benzothiazinone derivatives as anti-tuberculosis agents | The University Of Queensland (AU) | 2013-03-20 | — | — | EP | disclosed |
| WO-2012085654-A1 | NOVEL ANTI-TUBERCULOSIS AGENTS | THE UNIVERSITY OF QUEENSLAND (AU) | 2012-06-28 | — | — | WO | disclosed |
| EP-2468746-A1 | Benzothiazinone compounds and their use as anti-tuberculosis agents | The University of Queensland (AU) | 2012-06-27 | — | — | EP | disclosed |
| WO-2012066518-A1 | 2-PIPERAZIN-1-YL-4H-1,3-BENZOTHIAZIN-4-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF MAMMALIAN INFECTIONS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2012-05-24 | — | — | WO | disclosed |
| EP-2380886-A1 | Process for the preparation of 2-aminosubstituted 1,3-benzothiazine-4-ones | Makarov Vadim A. (RU) | 2011-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245007-A1 | 2-PIPERAZIN-1-YL-4H-1,3-BENZOTHIAZIN-4-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF MAMMALIAN INFECTIONS | BPGM, TBC1D5, TBC1D15 | CYP2C19 2625/4885PLK1 4097/4885KCNH2 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.